IRCT20170614034526N3已完成未知
Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 3 in patients undergoing hemodialysis- A Prospective interventional clinical trial
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Male & Female (non-pregnant)
- •being at the age of 18 years and over
- •End stage renal disease patients undergoing maintenance hemodialysis detected with HCV RNA by PCR.
排除标准
- •Patients having co-infection with HBV, HIV.
- •Patients with decompensated cirrhosis and terminal illness.
- •Patients hypersensitive to any of the ingredients of treatment drugs.
研究者
相似试验
已完成
不适用
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldCTRI/2020/06/025910Riten Kumar Samadder70
招募中
2 期
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
已完成
3 期
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
已完成
2 期
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
已完成
3 期
Hepatitis C Treatment in a Community-based SettingIRCT20170213032547N1Kerman University of Medical Sciences110